ALX ONCOLOGY HOLDINGS INC (ALXO)

Nasdaq Pharmaceutical Pharmaceutical Preparations SIC: 2834
D
Pipeline Grade

Financial Position (from SEC Filings)

$32.4M
Cash & Equivalents
$18.7M
Quarterly Burn Rate
5 mo
Est. Cash Runway
$264M
Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

Drug Pipeline (0 Assets)

No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.

Upcoming Catalysts

No upcoming catalysts detected for this company.

Active Clinical Trials (1)

NCT #TitlePhaseStatusEnrollment
NCT05467670 Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Recurrent Platin... PHASE2 Active Not Recruiting 16

Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for ALXO.

SEC EDGAR Filings

All SEC filings for ALX ONCOLOGY HOLDINGS INC on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.